Akari Therapeutics Announces Preclinical Ophthalmic Data Showing Nomacopan Reduces Both Vascular Endothelial Growth Factor (VEGF) and Retinal Inflammation Supporting Nomacopan as a Potential Treatment Option for Back-of-the-Eye Diseases

Daniel Sontupe
Market Access

Paul Theisen
Patient Acquisition

Amy Giles
Increasing Engagement

Liz Kane
Impactful Strategy

David Linetsky
Point-of-Care Marketing

Matthew Durham
Omnidynamic Marketing

Matt Turner
Patient Affordability

Pat Purcell
Meeting Engagement

Frank Burrell
Scientific Storytelling

Joey Cohen
Medication Adherence

Brenda Snow
Authentic Patient Voice

Suma Ramadas, PhD
Medical Affairs

Bud Bilanich
Success Coach

Stacey Gandler
Brand Nourishment